SUBSCRIBE
SUBSCRIBE

Metabolic disorders

Facade of Novo Nordisk's office in Fremont, California
Drug Development
Novo Takes Aim at Lilly’s Zepbound in Head-to-Head Trial Versus Wegovy Combo
Just a week after it secured FDA approval, Eli Lilly’s Zepbound now faces a challenge from Novo Nordisk’s investigational next-generation weight-loss candidate CagriSema in a Phase III trial.
November 16, 2023
 · 
2 min read
 · 
Tristan Manalac
FDA
Zepbound vs Wegovy: A Two-Horse Race
In this episode BioSpace’s Greg Slabodkin, Tyler Patchen and Lori Ellis discuss Zepbound, Wegovy, the weight loss race and the future of this drug class.
November 14, 2023
 · 
1 min read
Load More
PRESS RELEASES
Press Releases
Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes
May 14, 2025
 · 
7 min read
Press Releases
Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
May 14, 2025
 · 
6 min read
Press Releases
In new SELECT trial analysis, early reduction in cardiovascular events was observed with Wegovy®, before clinically meaningful changes in body weight
May 14, 2025
 · 
7 min read
Press Releases
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
May 14, 2025
 · 
8 min read
Press Releases
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
 · 
13 min read
Press Releases
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
May 12, 2025
 · 
7 min read
Press Releases
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
May 12, 2025
 · 
12 min read
Press Releases
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
May 12, 2025
 · 
7 min read
Press Releases
Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine
May 12, 2025
 · 
21 min read
Press Releases
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
May 9, 2025
 · 
8 min read
Press Releases
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™
May 9, 2025
 · 
4 min read
Press Releases
Novotech Analysis Highlights Rising Clinical Development Efforts for Obesity Treatments
May 8, 2025
 · 
2 min read
Press Releases
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
May 8, 2025
 · 
11 min read
Press Releases
ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update
May 7, 2025
 · 
8 min read
Press Releases
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes
May 7, 2025
 · 
8 min read
Press Releases
Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases
May 7, 2025
 · 
8 min read
Press Releases
Bluejay Therapeutics Reports First Preclinical Data for Liver-Targeted Fatty Acid Synthase (FASN) Inhibitor BJT-188 Being Investigated for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
May 7, 2025
 · 
5 min read
Press Releases
Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema
May 7, 2025
 · 
9 min read
Press Releases
Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity
May 6, 2025
 · 
2 min read
Press Releases
Novaremed Announces Completion of Enrollment in NIH-sponsored Phase 2b Study with Non-opioid NRD.E1 for the Treatment of Chronic Pain Associated with Diabetic Peripheral Neuropathy
May 6, 2025
 · 
6 min read
Load More